Elutia (ELUT, Financial) has officially launched a clinical study, named EluPro, aimed at gathering data on patient outcomes in routine clinical settings. This study involves the EluPro bioenvelope, a pioneering product that recently gained FDA clearance. It is uniquely designed to elute antibiotics and is intended for use with cardiac implantable electronic devices and neurostimulators. The commercial introduction of EluPro occurred earlier this year.
The first enrolment for the study took place at UC San Diego Health, marking a significant milestone for Elutia. The company emphasizes that the development of EluPro is a testament to its dedication to enhancing patient care. The product integrates established antibiotics with a gentle, regenerative biomatrix to shield the implant, simplify its insertion, and promote healing. The ongoing study will collect valuable data on these distinctive features as applied in real-world clinical practices.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Elutia Inc (ELUT, Financial) is $9.00 with a high estimate of $10.00 and a low estimate of $8.00. The average target implies an upside of 287.93% from the current price of $2.32. More detailed estimate data can be found on the Elutia Inc (ELUT) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Elutia Inc's (ELUT, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Elutia Inc (ELUT, Financial) in one year is $1.82, suggesting a downside of 21.55% from the current price of $2.32. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Elutia Inc (ELUT) Summary page.
